These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19838738)

  • 21. Cinacalcet: benefit and cost.
    Cohen E
    Nephrol Dial Transplant; 2008 Apr; 23(4):1460; author reply 1460. PubMed ID: 18065795
    [No Abstract]   [Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
    Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
    Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
    Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.
    Goodman WG; Hladik GA; Turner SA; Blaisdell PW; Goodkin DA; Liu W; Barri YM; Cohen RM; Coburn JW
    J Am Soc Nephrol; 2002 Apr; 13(4):1017-1024. PubMed ID: 11912261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
    Iseki K
    Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mineral metabolism: Should cinacalcet be used in patients who are not on dialysis?
    Cannata-Andía JB; Fernández-Martín JL
    Nat Rev Nephrol; 2009 Jun; 5(6):307-8. PubMed ID: 19474823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The influence of side effects related to cinacalcet therapy on compliance in hemodialysis patients suffering from secondary hyperparathyroidism].
    Zwiech R; Chrul S
    Wiad Lek; 2012; 65(3):145-50. PubMed ID: 23289260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.
    Yajima A; Akizawa T; Tsukamoto Y; Kurihara S; Ito A;
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S38-43. PubMed ID: 19032526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of cinacalcet withdrawal in Australian dialysis patients.
    Ruderman I; Holt SG; Kirkland GS; Maslen S; Hawley CM; Oliver V; Krishnasamy R; Gray NA; Talaulikar GS; Nelson CL; Rajaram Y; Gock H; Au E; Elder GJ; Mainra R; Toussaint ND
    Intern Med J; 2019 Jan; 49(1):48-54. PubMed ID: 29992701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet.
    Oshiro Y; Tanaka H; Okimoto N
    Clin Exp Nephrol; 2011 Aug; 15(4):607-10. PubMed ID: 21455660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study.
    Bonet J; Bayés B; Fernández-Crespo P; Casals M; López-Ayerbe J; Romero R
    Clin Nephrol; 2011 Mar; 75(3):181-7. PubMed ID: 21329627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
    Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C
    Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study.
    Schaefer RM; Bover J; Dellanna F; Sanz D; Asensio C; Sánchez González MC; Gross P; Zani V; Carter D; Jehle PM
    Clin Nephrol; 2008 Aug; 70(2):126-34. PubMed ID: 18793528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet.
    Chen P; Sohn W; Narayanan A; Gisleskog PO; Melhem M
    Br J Clin Pharmacol; 2019 Jun; 85(6):1312-1325. PubMed ID: 30756425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.
    Sprague SM; Evenepoel P; Curzi MP; González MT; Husserl FE; Kopyt N; Sterling LR; Mix C; Wong G
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1465-76. PubMed ID: 19696213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Więcek A
    Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.
    Zitt E; Rix M; Ureña Torres P; Fouque D; Jacobson SH; Pétavy F; Dehmel B; Ryba M
    Nephrol Dial Transplant; 2011 Jun; 26(6):1956-61. PubMed ID: 20947534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
    Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
    Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.